Company intelligence / Profile preview
Extend Biosciences
Newton, Massachusetts, USAextendbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Extend Biosciences has developed the proprietary D-VITylation® platform that attaches a vitamin D-based molecule to peptides/proteins, significantly improving their pharmacokinetics by reversible binding to serum vitamin D-binding protein. Their lead candidate, EXT608 for hypoparathyroidism, aims for once-weekly self-administration. Another program, EXT418 for cachexia and peripheral neuropathy, has completed efficacy studies and is IND-ready
- Therapeutic areas
- OncologyEndocrinologyNeurology
- Modalities
- PeptidesProteins
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Extend Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Extend Biosciences.